Skip to main content

Fiscal Wizard · Single-issue tearsheet

COR / Jun 21, 2026 Run #7439

COR

Cencora, Inc.

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Composite verdict

F 21.5 / 100
Bearish setup · Mean Reversion 9 drivers · 4 gates blocking
  • Stochastic RSI
  • ADX DI Cross
  • Stochastic Cross
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 7th of 12 in Medical Distribution

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 24 signals100% Bear
Momentum Bearish 28Mean-reversion Bearish 24
  • Late-stage trendTrend signals have been live for 66 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes fromMargin of safety -81%
Asset value $7.75Earnings power value $87.23Price $271.83

Priced above its no-growth earnings power value ($87.23/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

42.8 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
PEGY 0
Days Sales Outstanding 89
PEG 0
Payout Ratio 75
Margin of Safety 0

Technicals Bearish

0.2 / 100

Bearish setup leads (Stochastic RSI, ADX DI Cross, Stochastic Cross); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Stochastic RSI 15
Pin Bar 16
Stochastic Cross 17

Risk Gates

4 blocking 6 caution

4 guards active, 17 signals gated.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

LT Debt-to-Equity Blocking

High long-term D/E blocks bullish signals — structural-leverage risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for COR.